Sucampo Pharmaceuticals 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 25, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Sucampo Pharmaceuticals, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	44,258,268
Amendment Flag	'false	'
Entity Central Index Key	'0001365216	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$56,142	$44,102
Investments, current	15,534	16,003
Product royalties receivable	13,501	14,829
Unbilled accounts receivable	2	1
Accounts receivable, net	4,441	5,407
Prepaid and income taxes receivable	'	9
Deferred tax assets, current	2,148	2,028
Deferred charge, current	673	673
Restricted cash, current	26,115	26,115
Inventory	455	209
Prepaid expenses and other current assets	3,618	3,977
Total current assets	122,629	113,353
Investments, non-current	5,716	7,219
Property and equipment, net	1,084	1,156
Intangible assets, net	6,194	6,438
Deferred tax assets, non-current	1,314	1,212
Deferred charge, non-current	4,372	4,540
Restricted cash, non-current	2,481	2,471
Other assets	455	584
Total assets	144,245	136,973
Current liabilities:	'	'
Accounts payable	5,988	7,614
Accrued expenses	6,004	5,682
Deferred revenue, current	1,617	1,365
Income tax payable	694	701
Notes payable, current	27,348	26,892
Other current liabilities	1,922	358
Total current liabilities	43,573	42,612
Notes payable, non-current	25,819	25,828
Deferred revenue, non-current	5,998	6,169
Deferred tax liability, non-current	1,853	2,066
Other liabilities	1,596	2,150
Total liabilities	78,839	78,825
Commitments and contingencies (Note 7)	'	'
Additional paid-in capital	78,795	72,109
Accumulated other comprehensive income	15,490	15,601
Treasury stock, at cost; 524,792 and 524,792 shares	-2,313	-2,313
Accumulated deficit	-27,006	-27,681
Total stockholders' equity	65,406	58,148
Total liabilities and stockholders' equity	144,245	136,973
Common Class A [Member]	'	'
Current liabilities:	'	'
Common stock value	$440	$432

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	524,792
Common Class A [Member]	'	'
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	44,085,203	43,315,749
Common stock, shares outstanding	44,085,203	43,315,749
Common Class B [Member]	'	'
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Research and development revenue	$1,784	$2,800
Product royalty revenue	13,501	11,677
Product sales revenue	6,312	2,217
Co-promotion revenue	362	61
Contract and collaboration revenue	202	164
Total revenues	22,161	16,919
Costs and expenses:	'	'
Costs of goods sold	3,517	1,282
Research and development	5,135	5,629
General and administrative	7,257	7,227
Selling and marketing	3,647	5,389
Total costs and expenses	19,556	19,527
Income (loss) from operations	2,605	-2,608
Non-operating income (expense):	'	'
Interest income	57	19
Interest expense	-400	-495
Other income (expense), net	-323	1,081
Total non-operating income (expense), net	-666	605
Income (loss) before income taxes	1,939	-2,003
Income tax provision	-1,264	-1,142
Net income (loss)	675	-3,145
Net income (loss) per share:	'	'
Basic (in Dollars per share)	$0.02	($0.08)
Diluted (in Dollars per share)	$0.02	($0.08)
Weighted average common shares outstanding:	'	'
Basic (in Shares)	43,401	41,461
Diluted (in Shares)	44,264	41,461
Net income (loss)	675	-3,145
Other comprehensive income (loss):	'	'
Unrealized loss on investments, net of tax effect	7	-14
Foreign currency translation	-118	51
Comprehensive income (loss)	$564	($3,108)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholdersb Equity (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
In Thousands, except Share data	Common Class A [Member]
Balance, amount at Dec. 31, 2013	$432	$72,109	$15,601	($2,313)	($27,681)	$58,148
Balance, shares (in Shares) at Dec. 31, 2013	43,315,749	'	'	524,792	'	'
Employee stock option expense	'	228	'	'	'	228
Stock issued under exercise of stock options	2	1,114	'	'	'	1,116
Stock issued under exercise of stock options (in Shares)	230,140	'	'	'	'	'
Stock issued under employee stock purchase plan	'	5	'	'	'	5
Stock issued under employee stock purchase plan (in Shares)	793	'	'	'	'	'
Stock issued under "at-the-market" offering	6	5,321	'	'	'	5,327
Stock issued under "at-the-market" offering (in Shares)	538,521	'	'	'	'	'
Foreign currency translation	'	'	-118	'	'	-118
Unrealized loss on investments, net of tax effect	'	'	7	'	'	7
Windfall tax benefit from stock-based compensation	'	18	'	'	'	18
Net income	'	'	'	'	675	675
Balance, amount at Mar. 31, 2014	$440	$78,795	$15,490	($2,313)	($27,006)	$65,406
Balance, shares (in Shares) at Mar. 31, 2014	44,085,203	'	'	524,792	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$675	($3,145)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	361	381
Deferred tax provision	-395	114
Deferred charge	168	168
Stock-based compensation	228	412
Amortization of premiums on investments	26	27
Unrealized currency translations	210	63
Changes in operating assets and liabilities:	'	'
Accounts receivable	965	-481
Unbilled accounts receivable	-2	567
Product royalties receivable	1,328	2,498
Inventory	-245	-3,918
Prepaid and income taxes receivable and payable, net	-5	809
Accounts payable	-1,630	3,856
Accrued expenses	303	-2,629
Deferred revenue	48	-2,947
Accrued interest payable	359	460
Other assets and liabilities, net	1,167	-811
Net cash provided by (used in) operating activities	3,561	-4,576
Cash flows from investing activities:	'	'
Purchases of investments	'	-1,699
Proceeds from the sales of investments	1,700	'
Maturities of investments	250	3,360
Purchases of property and equipment	-41	-120
Changes in restricted cash	'	-9,561
Net cash provided by (used in) investing activities	1,909	-8,020
Cash flows from financing activities:	'	'
Proceeds from notes payable	'	10,600
Proceeds from exercise of stock options	1,116	'
Proceeds from employee stock purchase plan	5	5
Proceeds from "at-the-market" stock issuance	5,327	'
Purchase of treasury stock	'	-335
Windfall benefit from stock-based compensation	18	'
Net cash provided by financing activities	6,466	10,270
Effect of exchange rates on cash and cash equivalents	104	-1,053
Net increase (decrease) in cash and cash equivalents	12,040	-3,379
Cash and cash equivalents at beginning of period	44,102	52,022
Cash and cash equivalents at end of period	$56,142	$48,643

Note_1_Business_Organization_a

Note 1 - Business Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1	Business Organization and Basis of Presentation
	Description of the Business
	Sucampo Pharmaceuticals, Inc., or the Company, is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of ion channel activators known as prostones. The Company has pioneered the field of prostones. Prostones are naturally occurring fatty acid metabolites which originally thought to be biologically inactive. Prostones have emerged as a promising compound class with physiological activities that can be targeted for the treatment of unmet or underserved medical needs.
	We believe that prostones act locally to restore normal function in cells and tissues, and because they are quickly metabolized, their pharmacologic activity can be targeted to specific organs and tissues. Prostones possess a unique mechanism of action as highly potent and selective ion channel activators based on in vitro studies. Ion channels are integral parts of cell membranes that regulate the flow of specific ions into and out of cells. This regulation is key to the functioning of cells, such as metabolic processes and survival. As such, prostones are physiological mediators that may have a role in the restoration of cellular homeostasis and tissue regeneration.
	The Company’s prostone-based compounds target the ClC-2 (chloride) and big potassium, or BK, ion channels. Because these ion channels play an important role in physiology, targeted dosing of prostones may have broad applicability in many disease states in different organ systems. The Company has developed synthetic analogs of the naturally occurring prostones, which have been optimized to be more potent, selective, and stable, thus enabling their use as drugs. Prostones are very selective for their molecular targets, and the approved prostone-based compounds are well-tolerated and generally safe.
	The Company is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of the Company’s drug technologies.
	The Company currently generates revenue mainly from product royalties, development milestone payments, clinical development activities and product sales. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for AMITIZA® (lubiprostone), RESCULA® (unoprostone isopropyl) and other compounds, and commercializes the Company’s approved products on a global basis.
	To date, two prostone compounds – lubiprostone and unoprostone isopropyl - have received marketing approval under the brand names, AMITIZA and RESCULA, globally.
	In the United States, AMITIZA is marketed for three gastrointestinal indications under the October 2004 collaboration and license agreement with Takeda, or the Takeda Agreement. These indications are CIC in adults, irritable bowel syndrome with constipation, or IBS-C, in adult women and opioid-induced constipation, or OIC, in adults. Takeda also holds marketing rights to AMITIZA in Canada and steps are being taken to file for regulatory approval in Canada. The Company is primarily responsible for clinical development activities under the Takeda Agreement, while Takeda is primarily responsible for the commercialization of AMITIZA in the United States and Canada. The Company and Takeda initiated commercial sales of AMITIZA in the United States for the treatment of CIC, in April 2006, for the treatment of IBS-C in May 2008 and for the treat of OIC in May 2013.
	In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd., or Abbott, for the gastrointestinal indication of chronic constipation, or CC, excluding constipation caused by organic diseases. In early December 2013, the two-week limitation on prescriptions, generally applied to all new approvals of products for the first year after reimbursement price approval by the Japanese government was removed. AMITIZA is Japan’s only prescription medicine for CC.
	In Switzerland, the Company is commercializing AMITIZA for CIC. The Company announced in February 2014 that the Bundesamt fur Gesundheit revised several reimbursement limitations with which AMITIZA was first approved for reimbursement and inclusion in the Specialitätenliste to allow all Swiss physicians to prescribe AMITIZA to patients who have failed previous treatments with at least two laxatives over a nine month period. The Company filed for the OIC indication in Switzerland and anticipates a decision in the first half of 2014.
	In the United Kingdom, the Company is commercializing AMITIZA for CIC. In the first quarter of 2014, the submission for the National Institute for Health and Care Excellence endorsement for CIC was completed. The Company filed for the OIC indication in the United Kingdom and in March 2014, the Company received notification from Medicines and Healthcare Products Regulatory Agency that the application was not approved. The Company is exploring all available options for a path forward. The Company is also considering seeking approval for AMITIZA in other European Union countries for CIC following the Mutual Recognition Procedure. Since February 2012, AMITIZA has also been available through a Named Patient Program throughout the European Union, Iceland and Norway.
	The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure, or IOP, in patients with open-angle glaucoma or ocular hypertension. According to the U.S. approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator, which is different from other IOP lowering agents.
	The Company’s other clinical development programs include the following:
	Lubiprostone for a Reformulation and Pediatric Functional Constipation
	The new drug application for the liquid formulation of lubiprostone will not be filed in the second half of 2014 as the U.S. Food and Drug Administration will require additional data to characterize pharmacokinetics of the new formulation and a pharmacodynamics, pharmacokinetics, and tolerability study of the reformulation showed directional improvement, but not statistical significance, in spontaneous bowel movement frequency. Based on the findings, Takeda Pharmaceutical Company Limited, or Takeda, has agreed to fund 100% of the costs for the additional reformulation work for lubiprostone. As part of the pediatric development program, in March 2014, the Company’s first patient enrolled into a follow-on, open-label safety extension study of a global phase 3 clinical trial of lubiprostone in patients 6 to 17 years of age for pediatric functional constipation. This is the first of two open-label extension studies. One of the pediatric trials may use a new age appropriate formulation of lubiprostone.
	Intravenous and Oral Ion Channel Activators for Lumbar Spinal Stenosis
	Two ion channel activators, in both the intravenous, or IV, and oral, or PO, forms, are in clinical development for the treatment of lumbar spinal stenosis, or LSS. The Company initiated a phase 1b study to evaluate the safety and pharmacokinetic of an of the orally administered ion channel activator. This compound is in clinical development for LSS. This trial is expected to conclude in the third quarter of 2014. The Company plans to conduct an additional phase 2a study in the second half of 2014 to evaluate the clinical effectiveness of the intravenous ion channel activator with LSS.
	Cobiprostone as an Oral Spray for Oral Mucositis
	The Company completed a phase 1b clinical trial for the target indication of prevention and/or treatment of oral mucositis. The results of the phase 1b showed that cobiprostone was well-tolerated and revealed low systemic exposure.
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 12, 2014. The financial information as of March 31, 2014 and for the three months ended March 31, 2014 and March 31, 2013 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, or SAG, based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, Ltd., based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, Maryland, through which the Company conducts its North and South America operations; and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom. We liquidated Ambrent Investments S.à r.l., based in Luxembourg, at the end of 2013. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Revisions to Previously Issued Financial Statements
	The Company has revised the March 31, 2013 condensed consolidated statements of operations and comprehensive income (loss) to correct an error in the improper presentation of gross profit.  As a result of this revision, gross profit will be removed as a sub-total and cost of goods sold will be disclosed as an operating cost under the heading “Costs and expenses”.  Gross profit was presented on the condensed consolidated statements of operations and comprehensive income (loss) beginning in the period ended December 31, 2012 and for periods ended March 31, June 30 and September 30, 2013.
	In addition, the Company has revised the March 31, 2013 condensed consolidated statements of cash flows to correct an error in the classification of foreign exchange gains and losses in net cash used in operating activities, investing activities and the effect of exchange rates on cash and cash equivalents. The error in classification affects the year ended December 31, 2013 and the periods ended September 30, 2013, June 30, 2013 and March 31, 2013.
	The revisions had no impact on income from operations or net income and were determined to not be material to any previously issued financial statements. Accordingly, the Company will revise previously reported interim and annual periods in future filings. The following revisions have been made to the previously reported March 31, 2013 balances:
			Presentation as of March 31, 2013
	(In thousands)		As Previously			Revision			As Revised
			Reported			Adjustment
	Gross profit		$	15,637		$	(15,637	)	$	-
	Total costs and expenses			(18,245	)		(1,282	)		(19,527	)
	Net cash provided by (used in) operating activities			(5,639	)		1,063			(4,576	)
	Net cash provided by (used in) investing activities			(7,946	)		(74	)		(8,020	)
	Effect of exchange rates on cash and cash equivalents			(64	)		(989	)		(1,053	)

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2	Summary of Significant Accounting Policies
	Restricted Cash
	Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., or the Tokyo-Mitsubishi Bank; a loan agreement with The Mizuho Bank, Ltd., or the Mizuho Bank; a loan agreement between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million at both March 31, 2014 and December 31, 2013.
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of March 31, 2014 and December 31, 2013, approximately $20.7 million, or 19.5%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 71.2% and 86.8% of the Company’s total revenues for the three months ended March 31, 2014 and 2013, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 85.4% and 88.2% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at March 31, 2014 and December 31, 2013, respectively. Revenues from another unrelated party, Abbott, accounted for 27.5% and 13.1% of the Company’s total revenues for the three months ended March 31, 2014 and 2013. The Company depends significantly upon collaborations with Takeda and Abbott, and its revenues may be impacted if these relationships are disrupted.
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at March 31, 2014 and December 31, 2013 were less than the estimated fair values (see Note 9 below). The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.
	Accounts Receivable and Unbilled Accounts Receivable
	The Company has established an allowance for doubtful accounts of approximately $440,000 at both March 31, 2014 and December 31, 2013, related to certain disputed Takeda invoices.

Note_3_Net_Income_Loss_per_Sha

Note 3 - Net Income (Loss) per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3	Net Income (Loss) per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.
	The computation of net income (loss) per share for the three months ended March 31, 2014 and 2013 is shown below:
			Three Months Ended March 31,
	(in thousands, except per share data)		2014		2013
	Basic net income (loss) per share:
	Net income (loss)		$	675	$	(3,145	)
	Weighted average class A common shares outstanding			43,401		41,461
	Basic net income (loss) per share		$	0.02	$	(0.08	)
	Diluted net income (loss) per share:
	Net income (loss)		$	675	$	(3,145	)
	Weighted average class A common shares outstanding			43,401		41,461
	Assumed exercise of stock options under the treasury stock method			863		-
				44,264		41,461
	Diluted net income (loss) per share		$	0.02	$	(0.08	)
	The potentially dilutive securities used in the calculations of diluted net income per share are as follows:
			March 31,
	(In thousands)		2014		2013
	Employee stock options			2,663		-
	Non-employee stock options			343		-
	The following securities were excluded from the computation of diluted net income (loss) per share as their effect would be anti-dilutive:
			March 31,
	(In thousands)		2014		2013
	Employee stock options			342		3,422
	Non-employee stock options			-		450

Note_4_Current_and_NonCurrent_

Note 4 - Current and Non-Current Investments	3 Months Ended
	Mar. 31, 2014
Investments Schedule [Abstract]	'
Investment [Text Block]	'
	4	Current and Non-Current Investments
	At March 31, 2014 and December 31, 2013, current and non-current available-for-sale investments consisted of the following securities:
			31-Mar-14
	(In thousands)		Cost		Unrealized		Unrealized			Fair Value
					Gains		Losses
	Current:
	U.S. government securities		$	1,000	$	-	$	-		$	1,000
	U.S. government agencies			10,279		4		-			10,283
	Certificates of deposits			3,750		-		-			3,750
	Corporate bonds			501		-		-			501
	Total		$	15,530	$	4	$	-		$	15,534
	Non-current:
	U.S. government agencies		$	2,958	$	1	$	(2	)	$	2,957
	Certificates of deposit			2,250		-		-			2,250
	Corporate bonds			510		-		(1	)		509
	Total		$	5,718	$	1	$	(3	)	$	5,716
			31-Dec-13
	(In thousands)		Cost		Unrealized		Unrealized			Fair Value
					Gains		Losses
	Current:
	U.S. government securities		$	1,000	$	-	$	-		$	1,000
	U.S. government agencies			9,048		3		-			9,051
	Certificates of deposit			3,500		-		-			3,500
	Corporate bonds			752		-		-			752
	Municipal securities			1,700		-		-			1,700
	Total		$	16,000	$	3	$	-		$	16,003
	Non-current:
	U.S. government agencies		$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposits			2,500		-		-			2,500
	Corporate bonds			511		-		(1	)		510
	Total		$	7,223	$	-	$	(4	)	$	7,219
	The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:
	Level 1: quoted prices in active markets for identical assets or liabilities;
	Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, are as follows:
			Fair Value Measurements at Reporting Date Using
	(In thousands)		Quoted Prices		Significant		Significant			Total
			in Active		Other		Unobservable
			Markets for		Observable		Inputs
			Identical		Inputs		(Level 3)
			Assets		(Level 2)
			(Level 1)
	U.S. government securities		$	-	$	1,000	$	-		$	1,000
	U.S. government agencies			-		13,240		-			13,240
	U.S. commercial paper			-		8,824		-			8,824
	Certificates of deposit			-		6,000		-			6,000
	Corporate bonds			-		2,760		-			2,760
	Money market funds			8,098		-		-			8,098
	Total assets measured at fair value		$	8,098	$	31,824	$	-		$	39,922
			Fair Value Measurements at Reporting Date Using
	(In thousands)		Quoted Prices		Significant		Significant			Total
			in Active		Other		Unobservable
			Markets for		Observable		Inputs
			Identical		Inputs		(Level 3)
			Assets		(Level 2)
			(Level 1)
	U.S. government securities		$	-	$	1,000	$	-		$	1,000
	U.S. government agencies			-		13,260		-			13,260
	U.S. commercial paper			-		6,449		-			6,449
	Municipal securities			-		1,700		-			1,700
	Certificates of deposit			-		6,000		-			6,000
	Corporate bonds			-		5,533		-			5,533
Money market funds			5,955		-		-			5,955
Total assets measured at fair value		$	5,955	$	33,942	$	-		$	39,897
If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note_5_Intangible_Assets

Note 5 - Intangible Assets	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	5	Intangible Assets
	In April 2009, the Company entered into an agreement with R-Tech Ueno, Ltd, or R-Tech, or the 2009 R-Tech Agreement, to license all patents and other intellectual property rights related to RESCULA for its FDA approved indication and any new indications for unoprostone isopropyl in the United States and Canada. A supplemental new drug application for RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension was approved by the FDA in December 2012 and the Company began commercializing the product in February 2013.
	Under the terms of the 2009 R-Tech Agreement, the Company has made an upfront and milestone  payments of $3.5 million and may be required to pay up to $5.0 million in additional milestone payments based on the achievement of specified development and commercialization goals. The Company allocated the acquisition cost between an intangible asset of $3.4 million and a non-current prepaid inventory of $85,000. The $3.4 million intangible asset is included in intangible assets, net in the accompanying Condensed Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013. The non-current prepaid inventory of $85,000 was written-off during the year ended December 31, 2013. The cost of the intangible asset is being amortized over the 10-year life of the 2009 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $85,000 for each of the three months ended March 31, 2014 and 2013. The annual amortization expense will be approximately $341,000 through April 2019. The unamortized amount included in intangible assets was $1.7 million and $1.8 million at March 31, 2014 and December 31, 2013, respectively
	On March 22, 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, or the 2011 R-Tech Agreement, expanding the Company’s development and commercialization rights as well as its territories beyond their previously agreed territory of the United States and Canada to the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is now evaluating the opportunities to obtain an appropriate label in the E.U. and other European countries, and the timing of seeking reauthorization in those countries to commercialize unoprostone isopropyl.
	Pursuant to the 2011 R-Tech Agreement, the Company has made payments to R-Tech of $6.0 million, which is reflected in intangible assets, net in the accompanying Condensed Consolidated Balance Sheets, and may be required to pay up to $100.0 million in additional milestone payments to R-Tech based on the achievement of specified development and commercialization goals. The Company will be responsible for all development, regulatory, and commercialization activities. The Company is amortizing the $6.0 million over the 10-year life of the 2011 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $153,000 for each of the three months ended March 31, 2014 and 2013. The annual amortization expense will be approximately $613,000 through March 2021. The unamortized amount included in intangible assets was $4.3 million and $4.4 million at March 31, 2014 and December 31, 2013, respectively.
	The Company reviews intangible assets for impairment when events or changes in circumstances indicate that the carrying value of its intangible assets may not be recoverable. Impairment in the carrying value of an intangible asset is recognized whenever anticipated future undiscounted cash flows from an intangible asset are estimated to be less than its carrying value. There have been no impairment charges recorded during the three months ended March 31, 2014 and 2013 since there have been no indicators of impairment during those periods. If the Company’s actual results, or the plans and estimates used in future impairment analyses, are lower than the original estimates used to assess the recoverability of these assets, the Company could incur future impairment charges.

Note_6_Accrued_Expenses

Note 6 - Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6	Accrued Expenses
	Accrued expenses consist of the following:
	(In thousands)		March 31,		December 31,
			2014		2013
	Research and development costs		$	2,146	$	1,775
	Employee compensation			1,380		2,531
	Selling and marketing costs			252		584
	Legal service fees			347		14
	Other accrued expenses			1,879		778
	Total		$	6,004	$	5,682

Note_7_Commitments

Note 7 - Commitments	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	7	Commitments
	Operating Leases
	The Company leases office space in the United States, Switzerland and Japan under operating leases through 2018. Total future minimum, non-cancelable lease payments under operating leases are as follows:
	(In thousands of U.S. dollars)		March 31,
			2014
	2014		$	1,077
	2015			1,272
	2016			1,303
	2017			358
	2018			217
	Total minimum lease payments		$	4,227
	Rent expense for all operating leases was approximately $454,000 and $351,000 for the three months ended March 31, 2014 and 2013, respectively.
	Research and Development Costs
	The Company routinely enters into agreements with third-party contract research organizations to oversee clinical research and development studies provided on an outsourced basis, and to assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs under these agreements as of March 31, 2014 were approximately $7.4 million.
	Numab Commitment
	In the event that Numab defaults under its loan with Zurcher Kantonalbank, the Company’s maximum contingent liability under the Numab Agreement (as defined in Note 10) is $2.5 million. As of March 31, 2014, the potential amount of payments in the event of Numab’s default was $2.3 million. At March 31, 2014 the Company had a recorded liability of $810,000 in collateral callable to meet a potential loan default by Numab.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	8	Related Party Transactions
	R-Tech Ueno, Ltd.
	The Company recorded the following expenses under all of its agreements with R-Tech, including the 2009 R-Tech Agreement, the 2011 R-Tech Agreement and various exclusive supply agreements with R-Tech:
			Three Months Ended March 31,
	(In thousands)		2014		2013
	Clinical supplies		$	101	$	194
	Other research and development services			10		42
	Commercial supplies			3,547		1,837
			$	3,658	$	2,073
	The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech:
	(In thousands)		March 31,		December 31,
			2014		2013
	Deferred revenue, current		$	164	$	477
	Deferred revenue, non-current			5,092		4,925
			$	5,256	$	5,402
	The Company recognized approximately $164,000 and $163,000 of revenue relating to its agreements with R-Tech for the three months ended March 31, 2014 and 2013, respectively, which was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
	NittoMedic has received a letter from the FDA dated April 23, 2014 stating that its investigation of the NittoMedic facility has been closed and an establishment inspection report has been issued. Also, FDA has advised us that its review of the sNDA is proceeding on schedule with a decision expected in the 2nd quarter of 2014.
	Drs. Ryuji Ueno and Sachiko Kuno are married to each other and, directly or indirectly, own a majority of the stock of R-Tech. Drs. Ueno and Kuno are also controlling stockholders of the Company. Dr. Ueno was the Company’s Chief Executive Officer and Chairman of the Board and member through March 3, 2014, and was our Chief Scientific Officer through March 18, 2014.  On March 18, 2014, Dr. Ueno resigned from the Company and terminated the consulting agreement as previously announced on February 12, 2014.

Note_9_Notes_Payable

Note 9 - Notes Payable	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	9	Notes Payable
	In November 2010, the Company entered into a secured term loan agreement with the Tokyo-Mitsubishi Bank for ¥1,000,000,000, approximating $11.6 million as of the closing date. The loan renews every November. The interest rate at March 31, 2014 was 1.22%. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $9.7 million and $9.5 million as of March 31, 2014 and December 31, 2013, respectively. A deposit of $14.9 million with the Tokyo-Mitsubishi Bank collateralizing the loan bears annual interest of 0.25%.
	In March 2013, the Company entered into a secured term loan agreement with the Mizuho Bank for ¥1,000,000,000, approximating $10.6 million as of the closing date. The interest rate at March 31, 2014 was 0.46%. The loan renews every March. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $9.7 million and $9.5 million as of March 31, 2014 and December 31, 2013, respectively. A deposit of $11.0 million with the Mizuho Bank collateralizing the loan bears annual interest of 0.30%.
	In connection with the SAG acquisition in 2010, the Company issued a subordinated unsecured promissory note to each of the Ueno Trust and Kuno Trust. The interest rate beginning December 1, 2013 is 4.3%.
	Due to changes in LIBOR rates, the Company has estimated the fair value of the notes payable as shown in the table below.
	Notes payable at their fair value and carrying value consist of the following:
			Fair Value				Carrying Value
			March 31,		December 31,		March 31,		December 31,
	(In thousands)		2014		2013		2014		2013
	Loan agreements		$	19,455	$	19,008	$	19,455	$	19,008
	Promissory notes, Sellers of SAG			34,889		34,889		33,712		33,712
			$	54,344	$	53,897	$	53,167	$	52,720
	Notes payable, current						$	27,348	$	26,892
	Notes payable, non-current							25,819		25,828
							$	53,167	$	52,720
	The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 above, and is classified as a Level 2 security.

Note_10_Collaboration_and_Lice

Note 10 - Collaboration and License Agreements	3 Months Ended
	Mar. 31, 2014
Collaborative And License Arrangement Disclosure [Abstract]	'
Collaborative And License Arrangement Disclosure [Text Block]	'
	10	Collaboration and License Agreements
	Abbott Agreement
	The following table summarizes the cash streams and related revenue recognized or deferred under the Abbott Agreements for the three months ended March 31, 2014:
	(In thousands)		Amount		Cash Received		Revenue		Change in			Foreign			Amount
			Deferred at		for the Three		Recognized for		Accounts			Currency Effects			Deferred at
			December 31,		Months Ended		the Three		Receivable for			for the Three			March 31,
			2013		March 31,		Months Ended		the Three			Months Ended			2014
					2014		March 31,		Months Ended			March 31,
							2014		March 31,			2014
									2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees		$	555	$	-	$	10	$	-		$	13		$	558
	Product sales revenue:		$	-	$	5,933	$	6,077	$	196		$	(52	)	$	-
	Takeda agreements
	The Company has received a total of $150.0 million in upfront and development milestone payments through under the Takeda Agreement. Upon achievement of future development and commercialization milestones, the Company is potentially entitled to receive additional development milestone and commercialization milestone payments under the Takeda Agreement, although there can be no assurance that the Company will receive any such payments.
	The following table summarizes the cash streams and related revenue recognized or deferred under the Takeda Agreements for the three months ended March 31, 2014:
	(In thousands)		Amount		Cash Received		Revenue		Change in			Foreign			Amount
			Deferred at		for the Three		Recognized for		Accounts			Currency Effects			Deferred at
			December 31,		Months Ended		the Three		Receivable for			for the Three			March 31,
			2013		March 31,		Months Ended		the Three			Months Ended			2014
					2014		March 31,		Months Ended			March 31,
							2014		March 31,			2014
									2014*
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees		$	1,029	$	-	$	37	$	-		$	-		$	992
	Research and development revenue:
	Up-front payment - remainder		$	-	$	-	$	-	$	-		$	-		$	-
	Development milestones			-		-		-		-			-			-
	Reimbursement of research and development expenses			419		2,240		1,784		763			-			1,638
	Total		$	419	$	2,240	$	1,784	$	763		$	-		$	1,638
	Product royalty revenue		$	-	$	14,829	$	13,501	$	(1,328	)	$	-			-
	Co-promotion revenue		$	-	$	-	$	362	$	362		$	-			-
	*      Includes billed and unbilled accounts receivable.
	Numab AG
	In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or the Numab Agreement, with Numab. Until September 2013, Numab was considered a related party as a result of an ownership interest in Numab by one of the Company’s former executive officers, who resigned in September 2013. Under the terms of the Numab Agreement, the Company would provide Numab with up to CHF 5.0 million as collateral and would serve as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee during the first quarter of 2013, the collateral amount was reduced to CHF 2.2 million, or approximately $2.5 million as of March 31, 2014.
	As of March 31, 2014, the collateral of CHF 2.2 million has been deposited by the Company, and Numab has utilized CHF 2.0 million of its loan facility, or approximately $2.3 million. During 2012, the Company considered it probable that the success criteria for the first target would be met and made full provision for the success fee. This fee was paid during the first quarter of 2013. In the first quarter of 2013, the Company decided to no longer pursue further development of the target. In October 2013, Numab and the Company entered into a termination arrangement which may result in continued development by Numab. After successful development by Numab and an agreement with a third party investor, Numab and the Company will enter into a license agreement on commercially reasonable terms. At March 31, 2014 and December 31, 2013, the Company had a recorded liability of $810,000 and $663,000, respectively, in collateral callable to meet a potential loan default by Numab.

Note_11_Stock_Option_Plans

Note 11 - Stock Option Plans	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	11	Stock Option Plans
	A summary of the employee stock option activity for the three months ended March 31, 2014 under the Company’s Amended and Restated 2001 Stock Incentive Plan, or the 2001 Stock Incentive Plan, is presented below:
			Shares			Weighted		Weighted		Aggregate
						Average		Average		Intrinsic Value
						Exercise Price		Remaining
						Per Share		Contractual
								Term (Years)
	Options outstanding, December 31, 2013			146,200		$	10
	Options outstanding, March 31, 2014			146,200			10		2.09	$	-
	Options exercisable, March 31, 2014			146,200			10		2.09	$	-
	A summary of the employee stock option activity for the three months ended March 31, 2014 under the Company’s Amended and Restated 2006 Stock Incentive Plan is presented below:
			Shares			Weighted		Weighted		Aggregate
						Average		Average		Intrinsic Value
						Exercise Price		Remaining
						Per Share		Contractual
								Term (Years)
	Options outstanding, December 31, 2013			2,513,063		$	5.03
	Options granted			600,000			8.49
	Options exercised			(162,640	)		4.43
	Options forfeited			(90,000	)		4.42
	Options expired			(1,716	)		4.42
	Options outstanding, March 31, 2014			2,858,707			5.81		7.54	$	5,395,261
	Options exercisable, March 31, 2014			1,045,999			5.63		6.35	$	2,283,506
	The weighted average grant date fair value of options granted during the three months ended March 31, 2014 and the year ended December 31, 2013 was $8.49 and $7.36, respectively. As of March 31, 2014, approximately $740,000 of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 1.61 years.
	A summary of the non-employee stock option activity for the three months ended March 31, 2014 under the Company’s 2001 Stock Incentive Plan is presented below:
			Shares			Weighted		Weighted		Aggregate
						Average		Average		Intrinsic Value
						Exercise Price		Remaining
						Per Share		Contractual
								Term (Years)
	Options outstanding, December 31, 2013			410,000		$	5.85
	Options exercised			(67,500	)		5.85
	Options outstanding, March 31, 2014			342,500			5.85		1.08	$	445,250
	Options exercisable, March 31, 2014			342,500			5.85		1.08	$	445,250
	Employee Stock Purchase Plan
	Under the Company’s 2006 Employee Stock Purchase Plan, the Company received $5,386 and $4,871 upon the employees’ purchase of 793 and 784 shares of class A common stock during the three months ended March 31, 2014 and 2013, respectively.

Note_12_Income_Taxes

Note 12 - Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	12	Income Taxes
	For the three months ended March 31, 2014 and 2013, the Company recorded tax provisions of $1.3 million and $1.1 million, respectively. The tax provision for the three months ended March 31, 2014 primarily pertained to pre-tax profits generated by the Company’s U.S subsidiary and the Company’s U.S. and Japanese subsidiaries for the three months ended March 31, 2013.
	Uncertain Tax Positions
	The Company had an outstanding non-current income tax liability of approximately $1.1 million, including interest, for uncertain tax positions as of March 31, 2014. The amount represented the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements. As of March 31, 2014, $1.1 million is reflected as other liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of March 31, 2014 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. During the three months ended March 31, 2014, the liability for income taxes has increased approximately $373,000. This increase in the liability is primarily related to the filing positions taken in various jurisdictions related to income tax nexus.

Note_13_Segment_Reporting

Note 13 - Segment Reporting	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	13	Segment Reporting
	The following is a summary of financial information of the Company’s reportable geographic segments:
	(In thousands)		Americas			Europe			Asia			Consolidated
	Three Months Ended March 31, 2014
	Research and development revenue		$	1,784		$	-		$	-		$	1,784
	Product royalty revenue			13,501			-			-			13,501
	Product sales revenue			158			56			6,098			6,312
	Co-promotion revenue			362			-			-			362
	Contract and collaboration revenue			142			50			10			202
	Total revenues			15,947			106			6,108			22,161
	Cost of goods sold			150			25			3,342			3,517
	Research and development expenses			2,589			1,412			1,134			5,135
	Depreciation and amortization			188			166			7			361
	Other operating expenses			7,841			2,234			468			10,543
	Income (loss) from operations			5,179			(3,731	)		1,157			2,605
	Interest income			21			3			33			57
	Interest expense			(359	)		-			(41	)		(400	)
	Other non-operating expense, net			(3	)		48			(368	)		(323	)
	Income (loss) before income taxes		$	4,838		$	(3,680	)	$	781		$	1,939
	Capital expenditures		$	41		$	-		$	-		$	41
	Three Months Ended March 31, 2013
	Research and development revenue		$	2,800		$	-		$	-		$	2,800
	Product royalty revenue			11,677			-			-			11,677
	Product sales revenue			1			8			2,208			2,217
	Co-promotion revenue			61			-			-			61
	Contract and collaboration revenue			141			12			11			164
	Total revenues			14,680			20			2,219			16,919
	Cost of goods sold			23			5			1,254			1,282
	Research and development expenses			1,282			2,671			1,676			5,629
	Depreciation and amortization			122			250			9			381
	Other operating expenses			10,317			598			1,320			12,235
	Income (loss) from operations			2,936			(3,504	)		(2,040	)		(2,608	)
	Interest income			15			4			-			19
	Interest expense			-			(460	)		(35	)		(495	)
	Other non-operating expense, net			(16	)		(192	)		1,289			1,081
	Income (loss) before income taxes		$	2,935		$	(4,152	)	$	(786	)	$	(2,003	)
	Capital expenditures		$	14		$	103		$	3		$	120
	As of March 31, 2014
	Property and equipment, net		$	805		$	105		$	174		$	1,084
	Identifiable assets, net of intercompany loans and investments		$	110,787		$	17,035		$	16,423		$	144,245
	As of December 31, 2013
	Property and equipment, net		$	869		$	112		$	175		$	1,156
	Identifiable assets, net of intercompany loans and investments		$	95,350		$	23,843		$	17,780		$	136,973

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 12, 2014. The financial information as of March 31, 2014 and for the three months ended March 31, 2014 and March 31, 2013 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG, or SAG, based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, Ltd., based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, Maryland, through which the Company conducts its North and South America operations; and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom. We liquidated Ambrent Investments S.à r.l., based in Luxembourg, at the end of 2013. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Cash
	Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd., or the Tokyo-Mitsubishi Bank; a loan agreement with The Mizuho Bank, Ltd., or the Mizuho Bank; a loan agreement between Numab AG (Numab) and Zurcher Kantonalbank, which the Company serves as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.6 million at both March 31, 2014 and December 31, 2013.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of March 31, 2014 and December 31, 2013, approximately $20.7 million, or 19.5%, and $16.4 million, or 17.1%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	Revenues from Takeda, an unrelated party, accounted for 71.2% and 86.8% of the Company’s total revenues for the three months ended March 31, 2014 and 2013, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 85.4% and 88.2% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at March 31, 2014 and December 31, 2013, respectively. Revenues from another unrelated party, Abbott, accounted for 27.5% and 13.1% of the Company’s total revenues for the three months ended March 31, 2014 and 2013. The Company depends significantly upon collaborations with Takeda and Abbott, and its revenues may be impacted if these relationships are disrupted.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The carrying amounts of the notes payable at March 31, 2014 and December 31, 2013 were less than the estimated fair values (see Note 9 below). The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	'
	Accounts Receivable and Unbilled Accounts Receivable
	The Company has established an allowance for doubtful accounts of approximately $440,000 at both March 31, 2014 and December 31, 2013, related to certain disputed Takeda invoices.

Note_1_Business_Organization_a1

Note 1 - Business Organization and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	'
		Presentation as of March 31, 2013
	(In thousands)	As Previously			Revision			As Revised
		Reported			Adjustment
	Gross profit	$	15,637		$	(15,637	)	$	-
	Total costs and expenses		(18,245	)		(1,282	)		(19,527	)
	Net cash provided by (used in) operating activities		(5,639	)		1,063			(4,576	)
	Net cash provided by (used in) investing activities		(7,946	)		(74	)		(8,020	)
	Effect of exchange rates on cash and cash equivalents		(64	)		(989	)		(1,053	)

Note_3_Net_Income_Loss_per_Sha1

Note 3 - Net Income (Loss) per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months Ended March 31,
	(in thousands, except per share data)	2014		2013
	Basic net income (loss) per share:
	Net income (loss)	$	675	$	(3,145	)
	Weighted average class A common shares outstanding		43,401		41,461
	Basic net income (loss) per share	$	0.02	$	(0.08	)
	Diluted net income (loss) per share:
	Net income (loss)	$	675	$	(3,145	)
	Weighted average class A common shares outstanding		43,401		41,461
	Assumed exercise of stock options under the treasury stock method		863		-
			44,264		41,461
	Diluted net income (loss) per share	$	0.02	$	(0.08	)
Schedule of Potentially Dilutive Securities [Table Text Block]	'
		March 31,
	(In thousands)	2014		2013
	Employee stock options		2,663		-
	Non-employee stock options		343		-
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		March 31,
	(In thousands)	2014		2013
	Employee stock options		342		3,422
	Non-employee stock options		-		450

Note_4_Current_and_NonCurrent_1

Note 4 - Current and Non-Current Investments (Tables)	3 Months Ended
	Mar. 31, 2014
Investments Schedule [Abstract]	'
Available-for-sale Securities [Table Text Block]	'
		31-Mar-14
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	1,000	$	-	$	-		$	1,000
	U.S. government agencies		10,279		4		-			10,283
	Certificates of deposits		3,750		-		-			3,750
	Corporate bonds		501		-		-			501
	Total	$	15,530	$	4	$	-		$	15,534
	Non-current:
	U.S. government agencies	$	2,958	$	1	$	(2	)	$	2,957
	Certificates of deposit		2,250		-		-			2,250
	Corporate bonds		510		-		(1	)		509
	Total	$	5,718	$	1	$	(3	)	$	5,716
		31-Dec-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	1,000	$	-	$	-		$	1,000
	U.S. government agencies		9,048		3		-			9,051
	Certificates of deposit		3,500		-		-			3,500
	Corporate bonds		752		-		-			752
	Municipal securities		1,700		-		-			1,700
	Total	$	16,000	$	3	$	-		$	16,003
	Non-current:
	U.S. government agencies	$	4,212	$	-	$	(3	)	$	4,209
	Certificates of deposits		2,500		-		-			2,500
	Corporate bonds		511		-		(1	)		510
	Total	$	7,223	$	-	$	(4	)	$	7,219
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		Fair Value Measurements at Reporting Date Using
	(In thousands)	Quoted Prices		Significant		Significant			Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		13,240		-			13,240
	U.S. commercial paper		-		8,824		-			8,824
	Certificates of deposit		-		6,000		-			6,000
	Corporate bonds		-		2,760		-			2,760
	Money market funds		8,098		-		-			8,098
	Total assets measured at fair value	$	8,098	$	31,824	$	-		$	39,922
		Fair Value Measurements at Reporting Date Using
	(In thousands)	Quoted Prices		Significant		Significant			Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		13,260		-			13,260
	U.S. commercial paper		-		6,449		-			6,449
	Municipal securities		-		1,700		-			1,700
	Certificates of deposit		-		6,000		-			6,000
	Corporate bonds		-		5,533		-			5,533
	Money market funds		5,955		-		-			5,955
	Total assets measured at fair value	$	5,955	$	33,942	$	-		$	39,897

Note_6_Accrued_Expenses_Tables

Note 6 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	(In thousands)	March 31,		December 31,
		2014		2013
	Research and development costs	$	2,146	$	1,775
	Employee compensation		1,380		2,531
	Selling and marketing costs		252		584
	Legal service fees		347		14
	Other accrued expenses		1,879		778
	Total	$	6,004	$	5,682

Note_7_Commitments_Tables

Note 7 - Commitments (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	(In thousands of U.S. dollars)	March 31,
		2014
	2014	$	1,077
	2015		1,272
	2016		1,303
	2017		358
	2018		217
	Total minimum lease payments	$	4,227

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2014
Note 8 - Related Party Transactions (Tables) [Line Items]	'
Schedule of Related Party Transactions [Table Text Block]	'
		Three Months Ended March 31,
	(In thousands)	2014		2013
	Clinical supplies	$	101	$	194
	Other research and development services		10		42
	Commercial supplies		3,547		1,837
		$	3,658	$	2,073
Deferred Revenue [Member]	'
Note 8 - Related Party Transactions (Tables) [Line Items]	'
Schedule of Related Party Transactions [Table Text Block]	'
	(In thousands)	March 31,		December 31,
		2014		2013
	Deferred revenue, current	$	164	$	477
	Deferred revenue, non-current		5,092		4,925
		$	5,256	$	5,402

Note_9_Notes_Payable_Tables

Note 9 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		Fair Value				Carrying Value
		March 31,		December 31,		March 31,		December 31,
	(In thousands)	2014		2013		2014		2013
	Loan agreements	$	19,455	$	19,008	$	19,455	$	19,008
	Promissory notes, Sellers of SAG		34,889		34,889		33,712		33,712
		$	54,344	$	53,897	$	53,167	$	52,720
	Notes payable, current					$	27,348	$	26,892
	Notes payable, non-current						25,819		25,828
						$	53,167	$	52,720

Note_10_Collaboration_and_Lice1

Note 10 - Collaboration and License Agreements (Tables)	3 Months Ended
	Mar. 31, 2014
Abbott [Member]	'
Note 10 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	(In thousands)	Amount		Cash Received		Revenue		Change in			Foreign			Amount
		Deferred at		for the Three		Recognized for		Accounts			Currency Effects			Deferred at
		December 31,		Months Ended		the Three		Receivable for			for the Three			March 31,
		2013		March 31,		Months Ended		the Three			Months Ended			2014
				2014		March 31,		Months Ended			March 31,
						2014		March 31,			2014
								2014
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	555	$	-	$	10	$	-		$	13		$	558
	Product sales revenue:	$	-	$	5,933	$	6,077	$	196		$	(52	)	$	-
Takeda [Member]	'
Note 10 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	(In thousands)	Amount		Cash Received		Revenue		Change in			Foreign			Amount
		Deferred at		for the Three		Recognized for		Accounts			Currency Effects			Deferred at
		December 31,		Months Ended		the Three		Receivable for			for the Three			March 31,
		2013		March 31,		Months Ended		the Three			Months Ended			2014
				2014		March 31,		Months Ended			March 31,
						2014		March 31,			2014
								2014*
	Collaboration revenue:
	Up-front payment associated with the Company's obligation to participate in joint committees	$	1,029	$	-	$	37	$	-		$	-		$	992
	Research and development revenue:
	Up-front payment - remainder	$	-	$	-	$	-	$	-		$	-		$	-
	Development milestones		-		-		-		-			-			-
	Reimbursement of research and development expenses		419		2,240		1,784		763			-			1,638
	Total	$	419	$	2,240	$	1,784	$	763		$	-		$	1,638
	Product royalty revenue	$	-	$	14,829	$	13,501	$	(1,328	)	$	-			-
	Co-promotion revenue	$	-	$	-	$	362	$	362		$	-			-

Note_11_Stock_Option_Plans_Tab

Note 11 - Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		146,200		$	10
	Options outstanding, March 31, 2014		146,200			10		2.09	$	-
	Options exercisable, March 31, 2014		146,200			10		2.09	$	-
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		2,513,063		$	5.03
	Options granted		600,000			8.49
	Options exercised		(162,640	)		4.43
	Options forfeited		(90,000	)		4.42
	Options expired		(1,716	)		4.42
	Options outstanding, March 31, 2014		2,858,707			5.81		7.54	$	5,395,261
	Options exercisable, March 31, 2014		1,045,999			5.63		6.35	$	2,283,506
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2013		410,000		$	5.85
	Options exercised		(67,500	)		5.85
	Options outstanding, March 31, 2014		342,500			5.85		1.08	$	445,250
	Options exercisable, March 31, 2014		342,500			5.85		1.08	$	445,250

Note_13_Segment_Reporting_Tabl

Note 13 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	(In thousands)	Americas			Europe			Asia			Consolidated
	Three Months Ended March 31, 2014
	Research and development revenue	$	1,784		$	-		$	-		$	1,784
	Product royalty revenue		13,501			-			-			13,501
	Product sales revenue		158			56			6,098			6,312
	Co-promotion revenue		362			-			-			362
	Contract and collaboration revenue		142			50			10			202
	Total revenues		15,947			106			6,108			22,161
	Cost of goods sold		150			25			3,342			3,517
	Research and development expenses		2,589			1,412			1,134			5,135
	Depreciation and amortization		188			166			7			361
	Other operating expenses		7,841			2,234			468			10,543
	Income (loss) from operations		5,179			(3,731	)		1,157			2,605
	Interest income		21			3			33			57
	Interest expense		(359	)		-			(41	)		(400	)
	Other non-operating expense, net		(3	)		48			(368	)		(323	)
	Income (loss) before income taxes	$	4,838		$	(3,680	)	$	781		$	1,939
	Capital expenditures	$	41		$	-		$	-		$	41
	Three Months Ended March 31, 2013
	Research and development revenue	$	2,800		$	-		$	-		$	2,800
	Product royalty revenue		11,677			-			-			11,677
	Product sales revenue		1			8			2,208			2,217
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		141			12			11			164
	Total revenues		14,680			20			2,219			16,919
	Cost of goods sold		23			5			1,254			1,282
	Research and development expenses		1,282			2,671			1,676			5,629
	Depreciation and amortization		122			250			9			381
	Other operating expenses		10,317			598			1,320			12,235
	Income (loss) from operations		2,936			(3,504	)		(2,040	)		(2,608	)
	Interest income		15			4			-			19
	Interest expense		-			(460	)		(35	)		(495	)
	Other non-operating expense, net		(16	)		(192	)		1,289			1,081
	Income (loss) before income taxes	$	2,935		$	(4,152	)	$	(786	)	$	(2,003	)
	Capital expenditures	$	14		$	103		$	3		$	120
	As of March 31, 2014
	Property and equipment, net	$	805		$	105		$	174		$	1,084
	Identifiable assets, net of intercompany loans and investments	$	110,787		$	17,035		$	16,423		$	144,245
	As of December 31, 2013
	Property and equipment, net	$	869		$	112		$	175		$	1,156
	Identifiable assets, net of intercompany loans and investments	$	95,350		$	23,843		$	17,780		$	136,973

Note_1_Business_Organization_a2

Note 1 - Business Organization and Basis of Presentation (Details)	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Number of products in clinical development	2

Note_1_Business_Organization_a3

Note 1 - Business Organization and Basis of Presentation (Details) - Revision to Previously Issued Financial Statements (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Total costs and expenses	($19,556)	($19,527)
Net cash provided by (used in) operating activities	3,561	-4,576
Net cash provided by (used in) investing activities	1,909	-8,020
Effect of exchange rates on cash and cash equivalents	104	-1,053
Scenario, Previously Reported [Member]	'	'
Gross profit	'	15,637
Total costs and expenses	'	-18,245
Net cash provided by (used in) operating activities	'	-5,639
Net cash provided by (used in) investing activities	'	-7,946
Effect of exchange rates on cash and cash equivalents	'	-64
Restatement Adjustment [Member]	'	'
Gross profit	'	-15,637
Total costs and expenses	'	-1,282
Net cash provided by (used in) operating activities	'	1,063
Net cash provided by (used in) investing activities	'	-74
Effect of exchange rates on cash and cash equivalents	'	($989)

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
			Takeda [Member]	Takeda [Member]	Takeda [Member]	Takeda [Member]	Abbott [Member]	Abbott [Member]
			Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]
			Sales Revenue, Goods, Net [Member]	Sales Revenue, Goods, Net [Member]	Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]	Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]	Sales Revenue, Goods, Net [Member]	Sales Revenue, Goods, Net [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'	'	'	'
Restricted Cash and Cash Equivalents (in Dollars)	$28,600,000	$28.60	'	'	'	'	'	'
Cash, FDIC Insured Amount (in Dollars)	20,700,000	16,400,000	'	'	'	'	'	'
PercentageOfDepositWithinFederallyInsuredLimits	19.50%	17.10%	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	71.20%	86.80%	85.40%	88.20%	27.50%	13.10%
Allowance for Doubtful Accounts Receivable (in Dollars)	$440,000	$440,000	'	'	'	'	'	'

Note_3_Net_Income_Loss_per_Sha2

Note 3 - Net Income (Loss) per Share (Details) - Net Income (Loss) per Share (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basic net income (loss) per share:	'	'
Net income (loss) (in Dollars)	$675	($3,145)
Weighted average class A common shares outstanding	43,401	41,461
Assumed exercise of stock options under the treasury stock method	863	'
	44,264	41,461
Diluted net income (loss) per share (in Dollars per share)	$0.02	($0.08)
Basic net income (loss) per share (in Dollars per share)	$0.02	($0.08)

Note_3_Net_Income_Loss_per_Sha3

Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities [Line Items]	'
Potentially dilutive securities	863
Employee Stock Option [Member]	'
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities [Line Items]	'
Potentially dilutive securities	2,663
Non-Employee Stock Options [Member]	'
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dilutive Securities [Line Items]	'
Potentially dilutive securities	343

Note_3_Net_Income_Loss_per_Sha4

Note 3 - Net Income (Loss) per Share (Details) - Antidilutive Securities	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	342	3,422
Non-Employee Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	'	450

Note_4_Current_and_NonCurrent_2

Note 4 - Current and Non-Current Investments (Details) - Current and Non-Current Investments (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current [Member]	'	'
Current:	'	'
Cost	$15,530	$16,000
Unrealized gains	4	3
Fair value	15,534	16,003
Non-current [Member]	'	'
Current:	'	'
Cost	5,718	7,223
Unrealized gains	1	'
Unrealized losses	-3	-4
Fair value	5,716	7,219
US Government and Government Agencies and Authorities [Member] | Current [Member]	'	'
Current:	'	'
Cost	1,000	1,000
Fair value	1,000	1,000
US Government and Government Agencies and Authorities [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	2,958	4,212
Unrealized gains	1	'
Unrealized losses	-2	-3
Fair value	2,957	4,209
US Government Agencies Debt Securities [Member] | Current [Member]	'	'
Current:	'	'
Cost	10,279	9,048
Unrealized gains	4	3
Fair value	10,283	9,051
US Government Agencies Debt Securities [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	2,250	2,500
Fair value	2,250	2,500
Certificates of Deposit [Member] | Current [Member]	'	'
Current:	'	'
Cost	3,750	3,500
Fair value	3,750	3,500
Certificates of Deposit [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	510	'
Unrealized losses	-1	'
Fair value	509	'
Corporate Bond Securities [Member] | Current [Member]	'	'
Current:	'	'
Cost	501	752
Fair value	501	752
Corporate Bond Securities [Member] | Non-current [Member]	'	'
Current:	'	'
Cost	'	511
Unrealized losses	'	-1
Fair value	'	510
Municipal Bonds [Member] | Current [Member]	'	'
Current:	'	'
Cost	'	1,700
Fair value	'	$1,700

Note_4_Current_and_NonCurrent_3

Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	$8,098	$5,955
Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	31,824	33,942
Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	39,922	39,897
US Government and Government Agencies and Authorities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	1,000	1,000
US Government and Government Agencies and Authorities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	1,000	1,000
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	13,240	13,260
US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	13,240	13,260
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,824	6,449
Commercial Paper [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,824	6,449
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	6,000	6,000
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	6,000	6,000
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	2,760	5,533
Corporate Bond Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	2,760	5,533
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,098	5,955
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	8,098	5,955
Municipal Notes [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	1,700
Municipal Notes [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured at Fair Value on Recurring Basis [Line Items]	'	'
Assets at fair value	'	$1,700

Note_5_Intangible_Assets_Detai

Note 5 - Intangible Assets (Details) (USD $)

1 Months Ended

3 Months Ended

4 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

Apr. 30, 2009

Mar. 31, 2014

Apr. 30, 2009

Apr. 30, 2009

Dec. 31, 2013

Apr. 30, 2009

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Other Noncurrent Assets [Member]

Other Noncurrent Assets [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2011 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

2009 R-Tech Agreement [Member]

Non-current Prepaid Inventory [Member]

Non-current Prepaid Inventory [Member]

Note 5 - Intangible Assets (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Solution Percentage

0.15%

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Intangible Assets

'

'

'

'

'

$3,500,000

'

'

'

$6,000,000

'

'

MilestonePaymentsMaximumAmount

'

'

'

'

'

5,000,000

'

'

'

100,000,000

'

'

Finite-lived Intangible Assets Acquired

'

3,400,000

3,400,000

'

'

'

'

'

'

6,000,000

'

'

Payments to Acquire Other Productive Assets

'

'

'

85,000

'

'

'

'

'

'

'

'

Asset Impairment Charges

'

'

'

'

85,000

'

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'

'

'10 years

'

'

'10 years

'

'

Amortization of Intangible Assets

'

'

'

'

'

'

85,000

85,000

'

153,000

153,000

'

Finite-Lived Intangible Assets, Annual Amortization Expense

'

'

'

'

'

'

341,000

'

'

613,000

'

'

Finite-Lived Intangible Assets, Net

'

'

'

'

'

'

$1,700,000

'

$1,800,000

$4,300,000

'

$4,400,000

Note_6_Accrued_Expenses_Detail

Note 6 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]	'	'
Research and development costs	$2,146	$1,775
Employee compensation	1,380	2,531
Selling and marketing costs	252	584
Legal service fees	347	14
Other accrued expenses	1,879	778
Total	$6,004	$5,682

Note_7_Commitments_Details

Note 7 - Commitments (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Note 7 - Commitments (Details) [Line Items]	'	'
Operating Leases, Rent Expense	$454,000	$351,000
Future Estimated Research and Development Costs	7,400,000	'
Guarantee of Indebtedness of Others [Member]	'	'
Note 7 - Commitments (Details) [Line Items]	'	'
Loss Contingency, Range of Possible Loss, Maximum	2,500,000	'
Loss Contingency, Estimate of Possible Loss	2,300,000	'
Loss Contingency Accrual, Provision	$810,000	'

Note_7_Commitments_Details_Fut

Note 7 - Commitments (Details) - Future Minimum, Non-Cancelable Lease Payments (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Future Minimum, Non-Cancelable Lease Payments [Abstract]	'
2014	$1,077
2015	1,272
2016	1,303
2017	358
2018	217
Total minimum lease payments	$4,227

Note_8_Related_Party_Transacti2

Note 8 - Related Party Transactions (Details) (R-Tech [Member], USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
R-Tech [Member]	'	'
Note 8 - Related Party Transactions (Details) [Line Items]	'	'
Contracts Revenue	$164,000	$163,000

Note_8_Related_Party_Transacti3

Note 8 - Related Party Transactions (Details) - Expenses under Agreements with R-Tech (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Related Party Transaction [Line Items]	'	'
Expenses related to R-Tech	$3,658	$2,073
Clinical Supplies [Member]	'	'
Related Party Transaction [Line Items]	'	'
Expenses related to R-Tech	101	194
Other research and development services [Member]	'	'
Related Party Transaction [Line Items]	'	'
Expenses related to R-Tech	10	42
Commercial supplies [Member]	'	'
Related Party Transaction [Line Items]	'	'
Expenses related to R-Tech	$3,547	$1,837

Note_8_Related_Party_Transacti4

Note 8 - Related Party Transactions (Details) - Amounts Included in Deferred Revenue Resulting from Deferral of Upfront Payments Relating to Exclusive Supply Agreements with R-Tech (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Related Party Transaction [Line Items]	'	'
Deferred revenue, current	$1,617	$1,365
Deferred revenue, non-current	5,998	6,169
R-Tech [Member]	'	'
Related Party Transaction [Line Items]	'	'
Deferred revenue, current	164	477
Deferred revenue, non-current	5,092	4,925
	$5,256	$5,402

Note_9_Notes_Payable_Details

Note 9 - Notes Payable (Details)	Dec. 01, 2013	Mar. 31, 2014	Dec. 31, 2013	Nov. 30, 2010	Nov. 30, 2010	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Mar. 31, 2013
	Kuno and Ueno Trust [Member]	Tokyo-Mitsubishi Bank [Member]	Tokyo-Mitsubishi Bank [Member]	Tokyo-Mitsubishi Bank [Member]	Tokyo-Mitsubishi Bank [Member]	Mizuho Bank Limited [Member]	Mizuho Bank Limited [Member]	Mizuho Bank Limited [Member]	Mizuho Bank Limited [Member]
	Subordinated Unsecured Promissory Notes [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]	Secured Debt [Member]
		USD ($)	USD ($)	USD ($)	JPY (¥)	USD ($)	USD ($)	USD ($)	JPY (¥)
Note 9 - Notes Payable (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	'	$11,600,000	¥ 1,000,000,000	'	'	$10,600,000	¥ 1,000,000,000
Line of Credit Facility, Interest Rate at Period End	'	1.22%	'	'	'	'	'	'	'
Line of Credit Facility, Amount Outstanding	'	9,700,000	9,500,000	'	'	9,700,000	9,500,000	'	'
Interest-bearing Deposits in Banks and Other Financial Institutions	'	$14,900,000	'	'	'	$11,000,000	'	'	'
Weighted Average Rate Domestic Deposit	'	0.25%	'	'	'	0.30%	'	'	'
Line of Credit Facility, Interest Rate During Period	'	'	'	'	'	0.46%	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.30%	'	'	'	'	'	'	'	'

Note_9_Notes_Payable_Details_N

Note 9 - Notes Payable (Details) - Notes Payable (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	$54,344	$53,897
Note Payable Carrying Value	53,167	52,720
Notes payable, current	27,348	26,892
Notes payable, non-current	25,819	25,828
Mizuho Bank Limited [Member]	'	'
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	19,455	19,008
Note Payable Carrying Value	19,455	19,008
SAG [Member]	'	'
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]	'	'
Note Payable Fair Value	34,889	34,889
Note Payable Carrying Value	$33,712	$33,712

Note_10_Collaboration_and_Lice2

Note 10 - Collaboration and License Agreements (Details)	3 Months Ended	12 Months Ended			3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Sep. 30, 2011	Mar. 31, 2014
	Financial Guarantee [Member]	Financial Guarantee [Member]	Financial Guarantee [Member]	Financial Guarantee [Member]	Up Front Fee And Milestone Payment Arrangement [Member]
	Numab Agreement [Member]	Numab Agreement [Member]	Numab Agreement [Member]	Numab Agreement [Member]	Takeda [Member]
	USD ($)	USD ($)	CHF	Maximum [Member]	USD ($)
				CHF
Note 10 - Collaboration and License Agreements (Details) [Line Items]	'	'	'	'	'
Revenue Recognition, Milestone Method, Revenue Recognized	'	'	'	'	$150,000,000
Guarantor Obligations, Maximum Exposure, Undiscounted	2,500,000	'	2,200,000	5,000,000	'
Guarantor Obligations, Collateral Deposited (in Francs)	'	'	2,200,000	'	'
Guarantor Obligations, Current Carrying Value	2,300,000	'	2,000,000	'	'
Loss Contingency Accrual, Provision	$810,000	$663,000	'	'	'

Note_10_Collaboration_and_Lice3

Note 10 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred under Agreement (Abbott [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Collaborative Arrangement [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Amount Deferred	$558	$555
Revenue Recognized	10	'
Foreign Currency Effects	13	'
Product Sales Revenue [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Cash Received	5,933	'
Revenue Recognized	6,077	'
Accounts Receivable	196	'
Foreign Currency Effects	($52)	'

Note_10_Collaboration_and_Lice4

Note 10 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred under Agreement (Takeda [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Dec. 31, 2013
Up Front Payment Remainder [Member] | Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Accounts Receivable	'	[1]	'
Development Milestone [Member] | Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Accounts Receivable	'	[1]	'
Reimbursement Of Research And Development Expenses [Member] | Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Amount Deferred	1,638		419
Cash Received	2,240		'
Revenue Recognized	1,784		'
Accounts Receivable	763	[1]	'
Collaborative Arrangement [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Amount Deferred	992		1,029
Revenue Recognized	37		'
Accounts Receivable	'	[1]	'
Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Amount Deferred	1,638		419
Cash Received	2,240		'
Revenue Recognized	1,784		'
Accounts Receivable	763	[1]	'
Product Royalty Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Cash Received	14,829		'
Revenue Recognized	13,501		'
Accounts Receivable	-1,328	[1]	'
Co-promotion revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Revenue Recognized	362		'
Accounts Receivable	$362	[1]	'
[1]	Includes billed and unbilled accounts receivable.

Note_11_Stock_Option_Plans_Det

Note 11 - Stock Option Plans (Details) (USD $)	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2014	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2013
Note 11 - Stock Option Plans (Details) [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	8.49	'	'	7.36
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	740,000	'	'	'
Employee Stock Option [Member]	'	'	'	'
Note 11 - Stock Option Plans (Details) [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'1 year 222 days	'	'	'
Common Class A [Member] | 2006 Employee Stock Purchase Plan [Member]	'	'	'	'
Note 11 - Stock Option Plans (Details) [Line Items]	'	'	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans	793	5,386	4,871	784

Note_11_Stock_Option_Plans_Det1

Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity (USD $)	3 Months Ended	11 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
2001 Incentive Plan [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	146,200	146,200
Options Outstanding, Weighted Average Exercise Price Per Share	$10	$10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'2 years 32 days	'
Options exercisable	146,200	'
Options exercisable, Weighted Average Exercise Price Per Share	$10	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'2 years 32 days	'
Stock Incentive Plan 2006 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	2,858,707	2,513,063
Options Outstanding, Weighted Average Exercise Price Per Share	$5.81	$5.03
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'7 years 197 days	'
Options Outstanding, Aggregate Intrinsic Value	$5,395,261	'
Options granted	'	600,000
Options granted	'	$8.49
Options exercised	'	-162,640
Options exercised, Weighted Average Exercise Price Per Share	'	$4.43
Options forfeited	'	-90,000
Options forfeited	'	$4.42
Options expired	'	-1,716
Options expired	'	$4.42
Options exercisable	1,045,999	'
Options exercisable, Weighted Average Exercise Price Per Share	$5.63	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'6 years 127 days	'
Options exercisable, Aggregate Intrinsic Value	2,283,506	'
Non Employee Stock Plan 2001 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	342,500	410,000
Options Outstanding, Weighted Average Exercise Price Per Share	$5.85	$5.85
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'1 year 29 days	'
Options Outstanding, Aggregate Intrinsic Value	445,250	'
Options exercised	'	-67,500
Options exercised, Weighted Average Exercise Price Per Share	'	$5.85
Options exercisable	342,500	'
Options exercisable, Weighted Average Exercise Price Per Share	$5.85	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'1 year 29 days	'
Options exercisable, Aggregate Intrinsic Value	$445,250	'

Note_12_Income_Taxes_Details

Note 12 - Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'	'
Income Tax Expense (Benefit)	$1,264,000	$1,142,000	'
Liability for Uncertain Tax Positions, Noncurrent	1,100,000	'	'
Liability for Uncertain Tax Positions, Current	'	'	1,100,000
Increase (Decrease) in Income Taxes	$373,000	'	'

Note_13_Segment_Reporting_Deta

Note 13 - Segment Reporting (Details) - Financial Information by Reportable Geographic Segment (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'
Research and development revenue	$1,784	$2,800	'
Product royalty revenue	13,501	11,677	'
Product sales revenue	6,312	2,217	'
Co-promotion revenue	362	61	'
Contract and collaboration revenue	202	164	'
Total revenues	22,161	16,919	'
Cost of goods sold	3,517	1,282	'
Research and development expenses	5,135	5,629	'
Depreciation and amortization	361	381	'
Other operating expenses	10,543	12,235	'
Income (loss) from operations	2,605	-2,608	'
Interest income	57	19	'
Interest expense	-400	-495	'
Other non-operating expense, net	-323	1,081	'
Income (loss) before income taxes	1,939	-2,003	'
Capital expenditures	41	120	'
As of March 31, 2014	'	'	'
Property and equipment, net	1,084	'	1,156
Identifiable assets, net of intercompany loans and investments	144,245	'	136,973
Americas [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Research and development revenue	1,784	2,800	'
Product royalty revenue	13,501	11,677	'
Product sales revenue	158	1	'
Co-promotion revenue	362	61	'
Contract and collaboration revenue	142	141	'
Total revenues	15,947	14,680	'
Cost of goods sold	150	23	'
Research and development expenses	2,589	1,282	'
Depreciation and amortization	188	122	'
Other operating expenses	7,841	10,317	'
Income (loss) from operations	5,179	2,936	'
Interest income	21	15	'
Interest expense	-359	'	'
Other non-operating expense, net	-3	-16	'
Income (loss) before income taxes	4,838	2,935	'
Capital expenditures	41	14	'
As of March 31, 2014	'	'	'
Property and equipment, net	805	'	869
Identifiable assets, net of intercompany loans and investments	110,787	'	95,350
Europe [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Product sales revenue	56	8	'
Contract and collaboration revenue	50	12	'
Total revenues	106	20	'
Cost of goods sold	25	5	'
Research and development expenses	1,412	2,671	'
Depreciation and amortization	166	250	'
Other operating expenses	2,234	598	'
Income (loss) from operations	-3,731	-3,504	'
Interest income	3	4	'
Interest expense	'	-460	'
Other non-operating expense, net	48	-192	'
Income (loss) before income taxes	-3,680	-4,152	'
Capital expenditures	'	103	'
As of March 31, 2014	'	'	'
Property and equipment, net	105	'	112
Identifiable assets, net of intercompany loans and investments	17,035	'	23,843
Asia [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Product sales revenue	6,098	2,208	'
Contract and collaboration revenue	10	11	'
Total revenues	6,108	2,219	'
Cost of goods sold	3,342	1,254	'
Research and development expenses	1,134	1,676	'
Depreciation and amortization	7	9	'
Other operating expenses	468	1,320	'
Income (loss) from operations	1,157	-2,040	'
Interest income	33	'	'
Interest expense	-41	-35	'
Other non-operating expense, net	-368	1,289	'
Income (loss) before income taxes	781	-786	'
Capital expenditures	'	3	'
As of March 31, 2014	'	'	'
Property and equipment, net	174	'	175
Identifiable assets, net of intercompany loans and investments	$16,423	'	$17,780